Delveinsight

MARCH 2, 2021

Evotec, Chinook Therapeutics to Advance Chronic Kidney Diseases Therapy Market. Evotec and Chinook Therapeutics have collaborated to develop and discover precision medicine therapies for patients with chronic kidney diseases (CKD). UPPTHERA will have exclusive rights to those compounds, as per the agreement, for further development.

Drug Delivery 40

Drug Delivery Research Drugs Gene Editing 40

Roots Analysis

NOVEMBER 3, 2023

NAD + is involved in a wide range of cellular processes, including energy metabolism, DNA repair, and gene expression. There are several types of NAMPT inhibitors, including small molecules, peptides, and antibodies. Despite their potential therapeutic benefits, NAMPT inhibitors have faced several challenges in clinical development.

Development 40

Development Drugs Trials FDA Approval 40

Drug Discovery World

OCTOBER 16, 2023

Alchemab, on the other hand, has developed a highly differentiated platform which enables the identification of novel drug targets and therapeutics by analysis of patient antibody repertoires, drawing from the expertise in Cambridge to progress the company’s mission to build a broad pipeline of protective therapeutics for hard-to-treat diseases.

Drugs 75

Drugs Life Science Gene Therapy Genome 75

The Pharma Data

JUNE 28, 2021

Weill Cornell Medicine is committed to bringing our faculty’s innovations to market so that patients can benefit from the latest therapeutics,” said Dr. Lisa Placanica, Senior Managing Director Center for Technology Licensing at Weill Cornell Medicine. Bayer’s Xofigo (radium-223 dichloride) is the first and only approved TAT.

Licensing 52

Licensing Licensing Medicine Development 52

Drug Discovery World

APRIL 29, 2024

He holds a PhD in Chemistry for early work on antibody drug conjugates in 1987 and was awarded the Bioprocessing Lifetime Achievement Award in 2021. She previously worked at Vertex Pharmaceuticals as VP Global Marketing, and at Zealand Pharma as VP, US Sales and Marketing.

Drugs 52

Drugs Sales Gene Therapy Life Science 52

Drug Discovery World

NOVEMBER 13, 2023

Ahead of protein and antibody engineering conference PEGS Europe 2024 in Lisbon, DDW’s Megan Thomas looks at what to expect from each track of the annual biologics technology meeting. Hiroki Shirai, PhD, Coordinator, RIKEN Center for Computational Science, on: ‘Applying deep learning anomaly detection to antibody structures’.

Protein 59

Protein Antibody Engineer Scientist 59

Drug Discovery World

NOVEMBER 30, 2023

Lightcast is developing a novel, programmable microfluidic platform that allows precise and highly flexible control of individual microdroplets using software-generated light patterns. The company’s goal is to accelerate functional characterisation and shortenoptimisation time in antibody discovery and t-cell workflows.

Antibody 59

Antibody Protein Engineer In-Vivo 59

XTalks

JANUARY 19, 2024

Regulatory bodies have demonstrated preparedness for the surge in radiopharmaceuticals as evidenced by inaugural Chemistry, Manufacturing and Controls (CMC) Development and Readiness Pilot (CDRP) programs to expedite commercial manufacturing, US Food and Drug Administration (FDA) approvals and marketing authorizations.

DNA 66

DNA Radiology FDA Approval Development 66

The Pharma Data

DECEMBER 27, 2020

Notably, we never modify the DNA of these cells, which avoids some of the safety concerns that have been reported with certain gene-editing technologies. Finally, we seek to generate compelling clinical data to support moving into late-stage clinical trials and eventual marketing authorizations.

Manufacturing 52

Manufacturing Production Development Clinical Trials 52

The Pharma Data

DECEMBER 2, 2020

Results show the protocol demonstrated a 30Gb+ yield of long DNA reads raw data of an E. The FMv8 protocol introduces a needle-aspirate-based, cell-resuspension step prior to cell lysis that boosts DNA recovery. eTheRNA’s global programs will benefit from China Grand Pharma’s development, clinical and marketing input.

Drugs 52

Drugs Gene Editing Genome Genomics 52

XTalks

AUGUST 2, 2023

Join us as we present an in-depth analysis of each company’s revenue, net income, R&D investments, core therapeutic areas, market presence and strategic collaborations. is a global pharmaceutical company, working across both developed and emerging markets. 2022 Revenue: Pfizer reported an annual revenue of $100.33

Sales 98

Sales Manufacturing FDA Approval Life Science 98

The Pharma Data

OCTOBER 26, 2020

Updated follow-up data from a Phase 1/2 study of quavonlimab (MK-1308), a novel investigational anti-CTLA-4 antibody, in combination with KEYTRUDA in patients with advanced NSCLC also was presented; a Phase 3 study of quavonlimab coformulated with KEYTRUDA in first-line advanced NSCLC is planned. formerly known as Seattle Genetics, Inc.)

Sales 40

Sales Vaccination Vaccine Production 40

XTalks

OCTOBER 26, 2023

She has 23 years of experience working with clients to move vaccine candidates through the clinical development pipeline, including regulatory submission. The Flu versus COVID-19: Virology and Vaccines SARS-CoV-2 versus Influenza Virology Viruses contain genetic material that can either be RNA or DNA.

Vaccination 105

Vaccination Vaccine RNA Manufacturing 105

Drug Discovery World

MAY 30, 2023

From antibody-drug conjugates and RNA, to CRISPR and CAR-T therapy, DDW asked the drug discovery industry what the most important development in oncology over the last five years has been. We expect this field to grow significantly in the coming years as these and other earlier stage assets are developed. Here are their answers.

Research 52

Research Drugs Protein RNA 52

Drug Discovery World

OCTOBER 7, 2022

It is about going faster in progressing our innovation to market, taking things further along the value chain as we de-risk the early science. Our ability to invest in, or partner to access, new technologies and capabilities is also enhanced within the new structure, enabling us to move faster to progress our innovations to market. .

HR 52

HR Research Drugs Development 52

The Pharma Data

OCTOBER 14, 2020

Priothera will use the funds to progress the clinical development of mocravimod, a modulator of sphingosine 1 phosphate (S1P) receptors, to enhance the curative potential of allogeneic hematopoietic stem cell transplantation (HSCT) for treating AML. The funds will be used to bring Ori’s innovative manufacturing platform to the market.

Clinical Trials 52

Clinical Trials Clinical Trials Manufacturing Trials 52

XTalks

DECEMBER 24, 2020

Most antibody drugs and vaccines have been developed to target parts of the spike protein. These include remdesivir, baricitinib, dexamethasone and three antibody drugs. Antibody drugs were also developed as targeted COVID-19 treatments. Drug Approvals.

Life Science 111

Life Science Vaccination Vaccine Gene 111

XTalks

SEPTEMBER 14, 2020

Moderna, for one, recently reported positive results in older adults between 56 and 71, as well as those 71 years of age and older, who reportedly mounted levels of neutralizing antibodies against the SARS-CoV-2 virus after two doses of its vaccine that were comparable to those seen in younger adults. Johnson & Johnson’s COVID-19 Vaccine.

Vaccination 92

Vaccination Vaccine Antibody Life Science 92